Alpha Tau Medical Gets FDA Approval for Pancreatic Cancer Trial Expansion
Ticker: DRTSW · Form: 6-K · Filed: Feb 3, 2025 · CIK: 1871321
| Field | Detail |
|---|---|
| Company | Alpha Tau Medical Ltd. (DRTSW) |
| Form Type | 6-K |
| Filed Date | Feb 3, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: FDA approval, clinical trial, medical technology, cancer
TL;DR
FDA greenlights Alpha Tau's pancreatic cancer trial expansion to 30 patients.
AI Summary
On February 3, 2025, Alpha Tau Medical Ltd. announced that the FDA has approved a supplement to their Investigational Device Exemption (IDE) to expand their pilot trial for Alpha DaRT® in pancreatic cancer. The trial will now include thirty patients with locally advanced or metastatic disease, divided into two cohorts.
Why It Matters
This FDA approval allows Alpha Tau Medical to expand its clinical trial for pancreatic cancer, potentially bringing its Alpha DaRT® technology closer to broader patient access.
Risk Assessment
Risk Level: medium — The company is still in the pilot trial phase for a new medical technology, indicating significant development and regulatory hurdles remain.
Key Numbers
- 30 — Patients (Number of patients to be included in the expanded pilot trial for pancreatic cancer.)
Key Players & Entities
- Alpha Tau Medical Ltd. (company) — Registrant
- FDA (company) — Regulatory body approving trial
- Alpha DaRT® (product) — Medical technology being trialed
- February 3, 2025 (date) — Date of announcement
FAQ
What is the specific purpose of the IDE supplement approved by the FDA?
The IDE supplement allows Alpha Tau Medical to expand its pilot trial of Alpha DaRT® to include thirty patients with pancreatic cancer.
What type of pancreatic cancer patients will be included in the expanded trial?
The expanded trial will include patients with locally advanced or metastatic disease.
When was this announcement made?
The announcement was made on February 3, 2025.
What is the name of the technology being tested?
The technology being tested is called Alpha DaRT®.
What form was filed with the SEC regarding this announcement?
This announcement was made via a Form 6-K filing.
Filing Stats: 320 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2025-02-03 08:32:09
Filing Documents
- ea0229579-6k_alphatau.htm (6-K) — 12KB
- ea022957901ex99-1_alpha.htm (EX-99.1) — 9KB
- 0001213900-25-009128.txt ( ) — 22KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Alpha Tau Medical Ltd. Date: February 3, 2025 By: /s/ Uzi Sofer Uzi Sofer Chief Executive Officer 3